Propharma Group LLC

Propharma Group LLC, doing business as Acadeus, is a for-profit Subchapter S Corporation based in Raleigh, North Carolina that provides expert regulatory consulting, quality assurance, clinical research support, and pharmacovigilance services to federal healthcare and medical research agencies as a prime contractor on full-and-open (non-set-aside) federal contracts. The vendor competes exclusively without set-aside designations and holds no SBA certifications.

Acadeus operates across two distinct customer bases with sharply divergent contract profiles. The National Institutes of Health Clinical Center accounts for 82% of award count (23 awards) but only 25% of combined potential value at $9.9 million, reflecting steady engagement through numerous smaller BPA calls and delivery orders under the GSA Multiple Award Schedule. By contrast, the Food and Drug Administration anchors 73% of combined potential value ($29.2 million) through a single $25 million Indefinite Delivery/Indefinite Quantity contract for review of laboratory-developed tests and in vitro diagnostics, running through March 6, 2027, plus one $4.2 million delivery order completed in September 2024. A single $1 million GSA Federal Acquisition Service order and minor Department of Veterans Affairs and National Heart Lung and Blood Institute awards round out the portfolio. The vendor's top three customers by potential value (FDA, NIH Clinical Center, GSA FAS) represent 100% of awards.

Academeus delivers regulatory sciences, quality assurance operations, clinical research compliance, and pharmacovigilance support. Recent NIH Clinical Center work includes a $415,594 firm fixed-price purchase order for a Director of Quality Assurance position supporting the Center for Clinical Excellence (awarded January 31, 2026, through January 30, 2027), a $218,962 BPA call for Director of Quality Assurance services under the Expert Consultants Project (awarded September 29, 2025), and earlier BPA calls ranging from $87,418 for pharmacy compliance remediation (November 2021) to $1.061 million for quality assurance activities (April 2024). FDA work centers on laboratory-developed test and in vitro diagnostic review; the parent $25 million IDIQ launched March 7, 2022, with delivery orders extending through September 2024. The vendor also provided FDA audit consultation services to Veterans Integrated Service Network 6 in September–December 2023 for $21,833.

The vendor places 42 task orders under the GSA Multiple Award Schedule (combined potential value $18.9 million) and holds the single-award FDA IDIQ noted above. GSA Schedule labor offerings span 12 categories at hourly rates from $112.84 (Validation Engineer I, bachelor's, no experience required) to $301.90 (Director of Compliance, bachelor's, 15 years' experience), with no security-cleared positions. Representative mid-tier offerings include Compliance Consultant at $195.15/hr and Senior Compliance Consultant at $246.80/hr.

Activity has contracted substantially. Awards peaked in 2023 with seven; 2024, 2025, and 2026 combined account for five awards. Only one award (valued at $416 thousand) reaches ultimate completion within the next twenty-four months, creating minimal near-term recompete exposure. The vendor obligated $14.1 million (35% of potential value) across the 28 total awards, indicating selective deployment against the $40.1 million combined potential value. Propharma Group operates solely as a prime contractor with no subcontract footprint, meaning it does not sub to other primes and does not employ subs on its federal awards.